Guillain-Barré syndrome

[1]  Richard J Barohn,et al.  Supportive care for patients with Guillain-Barré syndrome. , 2005, Archives of neurology.

[2]  P. V. van Doorn,et al.  Distinguishing acute-onset CIDP from Guillain–Barré syndrome with treatment related fluctuations , 2005, Neurology.

[3]  J. Schessl,et al.  Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barré Syndrome: A Randomized Trial , 2005, Pediatrics.

[4]  J. Li,et al.  Antecedent infections in Fisher syndrome , 2005, Neurology.

[5]  R. Hughes,et al.  Severity of Guillain–Barré syndrome is associated with Fcγ Receptor III polymorphisms , 2005, Journal of Neuroimmunology.

[6]  M. Mori,et al.  Recovery patterns and long term prognosis for axonal Guillain–Barré syndrome , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  N. Yuki,et al.  Patterns and serial changes in electrodiagnostic abnormalities of axonal Guillain–Barré syndrome , 2005, Neurology.

[8]  Kazuro Furukawa,et al.  Overexpression of GD1a Ganglioside Sensitizes Motor Nerve Terminals to Anti-GD1a Antibody-Mediated Injury in a Model of Acute Motor Axonal Neuropathy , 2005, The Journal of Neuroscience.

[9]  J. Jakobsen,et al.  Residual neuropathy in long-term population-based follow-up of Guillain–Barré syndrome , 2005, Neurology.

[10]  J. Meulstee,et al.  HLA class II alleles are not a general susceptibility factor in Guillain–Barré syndrome , 2005, Neurology.

[11]  E. Stålberg,et al.  Electrophysiological signs of permanent axonal loss in a follow‐up study of patients with Guillain–Barré syndrome , 2005, Muscle & nerve.

[12]  D. Bechtold,et al.  Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. , 2004, Brain : a journal of neurology.

[13]  J. Bussmann,et al.  Physical training and fatigue, fitness, and quality of life in Guillain–Barré syndrome and CIDP , 2004, Neurology.

[14]  T. Miyatake,et al.  Neurophysiological and immunohistochemical studies on Guillain-Barré syndrome with IgG anti-GalNAc-GD1a antibodies—effects on neuromuscular transmission , 2004, Journal of the Neurological Sciences.

[15]  V. Ghali,et al.  Blood γδ T cells, Campylobacter jejuni, and GM1 titers in Guillain–Barré syndrome , 2004 .

[16]  A. Todd,et al.  Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. , 2004, Brain : a journal of neurology.

[17]  N. Yuki,et al.  Does Campylobacter jejuni infection elicit “demyelinating” Guillain–Barré syndrome? , 2004, Neurology.

[18]  K. Hirata,et al.  Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Ettore Beghi,et al.  Incidence and clinical features of acute inflammatory polyradiculoneuropathy in Lombardy, Italy, 1996 , 2004, Acta neurologica Scandinavica.

[20]  H. Hartung,et al.  Advances in understanding and treatment of immune‐mediated disorders of the peripheral nervous system , 2004, Muscle & nerve.

[21]  R. Schnaar,et al.  An anti‐ganglioside antibody‐secreting hybridoma induces neuropathy in mice , 2004, Annals of neurology.

[22]  R. Hughes,et al.  Guillain-Barré syndrome , 2004, The Lancet.

[23]  M. Dalakas,et al.  Intravenous immunoglobulin in autoimmune neuromuscular diseases. , 2004, JAMA.

[24]  J. Laman,et al.  Functional polymorphisms in LPS receptors CD14 and TLR4 are not associated with disease susceptibility or Campylobacter jejuni infection in Guillain–Barré patients , 2004, Journal of Neuroimmunology.

[25]  P. V. D. Van den Bergh,et al.  Electrodiagnostic criteria for acute and chronic inflammatory demyelinating polyradiculoneuropathy , 2004, Muscle & nerve.

[26]  K. Hirata,et al.  Acute motor axonal neuropathy after Mycoplasma infection , 2004, Neurology.

[27]  L. H. van den Berg,et al.  Pathogenicity of anti-ganglioside antibodies in the Guillain-Barré syndrome. , 2004, Autoimmunity reviews.

[28]  J. Laman,et al.  The Guillain-Barré syndrome: a true case of molecular mimicry. , 2004, Trends in immunology.

[29]  J. Meulstee,et al.  Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial , 2004, The Lancet.

[30]  H. Willison,et al.  Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. , 2003, Brain : a journal of neurology.

[31]  P. Lampert.  Electron microscopic studies on ordinary and hyperacute experimental allergic encephalomyelitis , 2004, Acta Neuropathologica.

[32]  E. Granieri,et al.  Is there a decrease in Guillain–Barré syndrome incidence after bovine ganglioside withdrawal in Italy? A population-based study in the Local Health District of Ferrara, Italy , 2003, Journal of the Neurological Sciences.

[33]  S. Oh,et al.  Subacute inflammatory demyelinating polyneuropathy , 2003, Neurology.

[34]  D. Burke,et al.  The refractory period of transmission is impaired in axonal Guillain–Barré syndrome , 2003, Muscle & nerve.

[35]  R. Hughes,et al.  A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome , 2003, Neurology.

[36]  J. Stevens,et al.  Practice parameter: Immunotherapy for Guillain–Barré syndrome , 2003, Neurology.

[37]  K. Hirata,et al.  Acute motor axonal neuropathy rabbit model: Immune attack on nerve root axons , 2003, Annals of neurology.

[38]  I. Kanazawa,et al.  GalNAc-GD1a in human peripheral nerve , 2003, Neurology.

[39]  M. Mori,et al.  Differences in patterns of progression in demyelinating and axonal Guillain–Barré syndromes , 2003, Neurology.

[40]  K. Hirata,et al.  CDR3 spectratyping analysis of the T cell receptor repertoire in Guillain–Barré and Fisher syndromes , 2003, Journal of Neuroimmunology.

[41]  K. Hirata,et al.  Patients with chronic inflammatory demyelinating polyneuropathy initially diagnosed as Guillain-Barré syndrome , 2003, Journal of Neurology.

[42]  L. H. van den Berg,et al.  Anti–GM1 IgG antibodies induce leukocyte effector functions via Fcγ receptors , 2003 .

[43]  A. Chiò,et al.  Guillain-Barré syndrome , 2003, Neurology.

[44]  G. Mckhann,et al.  Differential Distribution of HLA-DQβ/DRβ Epitopes in the Two Forms of Guillain-Barré Syndrome, Acute Motor Axonal Neuropathy and Acute Inflammatory Demyelinating Polyneuropathy (AIDP): Identification of DQβ Epitopes Associated with Susceptibility to and Protection from AIDP1 , 2003, The Journal of Immunology.

[45]  I. Kanazawa,et al.  Binding of immunoglobulin G antibodies in Guillain–Barré syndrome sera to a mixture of GM1 and a phospholipid: Possible clinical implications , 2003, Muscle & nerve.

[46]  R. Hughes,et al.  Accumulation of immunoglobulin across the ‘blood–nerve barrier’ in spinal roots in adoptive transfer experimental autoimmune neuritis , 2002, Neuropathology and applied neurobiology.

[47]  H. Willison,et al.  Peripheral neuropathies and anti-glycolipid antibodies. , 2002, Brain : a journal of neurology.

[48]  R. Schnaar,et al.  Localization of major gangliosides in the PNS: implications for immune neuropathies. , 2002, Brain : a journal of neurology.

[49]  P. Schmitz,et al.  Long-term impact on work and private life after Guillain–Barré syndrome , 2002, Journal of the Neurological Sciences.

[50]  R. Hughes,et al.  Risk of relapse of Guillain-Barré syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation , 2002, Journal of neurology, neurosurgery, and psychiatry.

[51]  A. Moran,et al.  Campylobacter jejuni from Patients with Guillain-Barré Syndrome Preferentially Expresses a GD1a-Like Epitope , 2002, Infection and Immunity.

[52]  S. Kuwabara,et al.  Autonomic function in demyelinating and axonal subtypes of Guillain–Barré syndrome , 2002, Acta neurologica Scandinavica.

[53]  S. Fredrikson,et al.  Distinct pattern of age-specific incidence of Guillain-Barré syndrome in Harbin, China , 2002, Journal of Neurology.

[54]  E. Granieri,et al.  Epidemiology of the Guillain-Barré syndrome , 2001, Current opinion in neurology.

[55]  A. Montag,et al.  Development of Spontaneous Autoimmune Peripheral Polyneuropathy in B7-2–Deficient Nod Mice , 2001, The Journal of experimental medicine.

[56]  N. Yuki,et al.  Miller Fisher syndrome and Haemophilus influenzae infection , 2001, Neurology.

[57]  M. Pinter,et al.  Sodium channel inactivation in an animal model of acute quadriplegic myopathy , 2001, Annals of neurology.

[58]  A. Ropper,et al.  Mild Guillain-Barré syndrome. , 2001, Archives of neurology.

[59]  H. Endtz,et al.  Gastroenteritis-associated Guillain–Barré syndrome on the Caribbean Island Curaçao , 2001, Neurology.

[60]  K. Hirata,et al.  Animal model of axonal Guillain‐Barré syndrome induced by sensitization with GM1 ganglioside , 2001, Annals of neurology.

[61]  F. Baas,et al.  Investigation of serum response to PMP22, connexin 32 and P0 in inflammatory neuropathies , 2001, Journal of Neuroimmunology.

[62]  P. Gordon,et al.  Early electrodiagnostic findings in Guillain-Barré syndrome. , 2001, Archives of neurology.

[63]  B. Trapp,et al.  Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. , 2001, Brain : a journal of neurology.

[64]  K. Bulsara,et al.  GUILLAIN-BARRE SYNDROME IN ORGAN AND BONE MARROW TRANSPLANT PATIENTS , 2001, Transplantation.

[65]  H. Hartung,et al.  Preceding infections, immune factors, and outcome in Guillain–Barré syndrome , 2001, Neurology.

[66]  N. Yuki,et al.  Axonal Guillain‐Barré syndrome: Relation to anti‐ganglioside antibodies and Campylobacter jejuni infection in Japan , 2000, Annals of neurology.

[67]  E. Beghi,et al.  Guillain-Barré syndrome: an Italian multicentre case-control study , 2000, Neurological Sciences.

[68]  F. Bolgert,et al.  Cost analysis of plasma-exchange therapy for the treatment of Guillain-Barré syndrome , 2000, Intensive Care Medicine.

[69]  H. Willison,et al.  Randomized controlled trial of brain‐derived neurotrophic factor in Guillain–Barré syndrome: a pilot study , 2000, European journal of neurology.

[70]  R. Hughes,et al.  Anti-PMP22 antibodies in patients with inflammatory neuropathy , 2000, Journal of Neuroimmunology.

[71]  P. Schmitz,et al.  Mild forms of Guillain-Barré syndrome in an epidemiologic survey in the Netherlands , 2000, Neurology.

[72]  R. Hughes,et al.  Pathogenesis of Guillain–Barré syndrome , 1999, Journal of Neuroimmunology.

[73]  P. Schmitz,et al.  Fatigue in immune-mediated polyneuropathies , 1999, Neurology.

[74]  T. Sharshar,et al.  Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barré syndrome , 1999, Neurology.

[75]  N. Fejerman,et al.  Epidemiological, clinical, and electrodiagnostic findings in childhood Guillain‐Barré syndrome: A reappraisal , 1999, Annals of neurology.

[76]  H. Willison,et al.  Amendment history : Erratum ( December 1999 ) Monoclonal antibodies raised against Guillain-Barré syndrome – associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations , 2018 .

[77]  J. Meulstee,et al.  Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange , 1999, Neurology.

[78]  N. Yuki,et al.  Axonal involvement at the common entrapment sites in Guillain‐Barré syndrome with IgG anti‐GM1 antibody , 1999, Muscle & nerve.

[79]  P. Schmitz,et al.  Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome , 1999, Neurology.

[80]  E. Adachi-Usami,et al.  Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain–Barré syndrome , 1999, Neurology.

[81]  R. Hughes,et al.  Antiganglioside antibodies in Guillain-Barré syndrome after a recent cytomegalovirus infection , 1999, Journal of neurology, neurosurgery, and psychiatry.

[82]  M. Daha,et al.  Miller Fisher anti‐GQ1b antibodies: α‐Latrotoxin–like effects on motor end plates , 1999 .

[83]  G. Mckhann,et al.  Anti‐GD1a antibody is associated with axonal but not demyelinating forms of Guillain‐Barré syndrome , 1999, Annals of neurology.

[84]  L. Magder,et al.  The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. , 1998, The New England journal of medicine.

[85]  H. Kawakami,et al.  Genetic contribution of the tumor necrosis factor region in guillain‐barré syndrome , 1998, Annals of neurology.

[86]  R. Hughes,et al.  Induction of experimental autoimmune neuritis with peripheral myelin protein-22. , 1998, Brain : a journal of neurology.

[87]  H. Kawakami,et al.  HLA and T-cell receptor gene polymorphisms in Guillain-Barré syndrome , 1998, Neurology.

[88]  R. Hughes,et al.  The distribution of CD1 molecules in inflammatory neuropathy , 1998, Journal of the Neurological Sciences.

[89]  M. Pinter,et al.  Loss of electrical excitability in an animal model of acute quadriplegic myopathy , 1998, Annals of neurology.

[90]  H. Obayashi,et al.  Antibodies to gangliosides and galactocerebroside in patients with Guillain–Barré syndrome with preceding Campylobacter jejuni and other identical infections , 1998, Journal of Neuroimmunology.

[91]  J H Rees,et al.  Epidemiological study of Guillain-Barré syndrome in south east England , 1998, Journal of neurology, neurosurgery, and psychiatry.

[92]  I. Wirguin,et al.  Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome , 1997, The Lancet.

[93]  J. Ernerudh,et al.  T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barré syndrome , 1997, Journal of the Neurological Sciences.

[94]  R. Hughes,et al.  Clinical and epidemiologic features of Guillain-Barré syndrome. , 1997, The Journal of infectious diseases.

[95]  G. Mckhann,et al.  Differential distribution of HLA alleles in two forms of Guillain-Barré syndrome. , 1997, The Journal of infectious diseases.

[96]  K. Shindo,et al.  The physiological effect of anti-GM1 antibodies on saltatory conduction and transmembrane currents in single motor axons. , 1997, Brain : a journal of neurology.

[97]  J. Meythaler,et al.  Rehabilitation of Guillain-Barré syndrome. , 1997, Archives of physical medicine and rehabilitation.

[98]  M. Berciano,et al.  Fulminant Guillain–Barré Syndrome with universal inexcitability of peripheral nerves: A clinicopathological study , 1997, Muscle & nerve.

[99]  A. de Jager,et al.  Residual health status after Guillain-Barré syndrome. , 1997, Journal of neurology, neurosurgery, and psychiatry.

[100]  G. Mckhann,et al.  Patterns of recovery in the Guillain-Barre syndromes , 1997, Neurology.

[101]  I. Kanazawa,et al.  Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome , 1997, Brain Research.

[102]  A. Ben-Smith,et al.  Isolation and characterisation of T lymphocytes from sural nerve biopsies in patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[103]  G. Mckhann,et al.  Acute motor axonal neuropathy: An antibody‐mediated attack on axolemma , 1996, Annals of neurology.

[104]  G. Mckhann,et al.  Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy , 1996, Annals of neurology.

[105]  I. Kanazawa,et al.  Experimental sensory neuropathy induced by sensitization with ganglioside GD1b , 1996, Annals of neurology.

[106]  G. Mckhann,et al.  Pathology of the motor‐sensory axonal Guillain‐Barré syndrome , 1996, Annals of neurology.

[107]  J W Griffin,et al.  Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome , 1996, Journal of neurocytology.

[108]  R. Hughes,et al.  Campylobacter jejuni infection and Guillain-Barré syndrome. , 1995, The New England journal of medicine.

[109]  R. Vaughan,et al.  HLA-class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection , 1995, Journal of Neuroimmunology.

[110]  Josep Maria Salanova Grau,et al.  Acute axonal Guillain‐Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides , 1995, Annals of neurology.

[111]  G. Mckhann,et al.  Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. , 1995, Brain : a journal of neurology.

[112]  M. Blaser,et al.  Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. , 1995, Brain : a journal of neurology.

[113]  R. Kikkawa,et al.  Antibodies against GM1 ganglioside affect K+ and NA+ currents in isolated rat myelinated nerve fibers , 1995, Annals of neurology.

[114]  H. Hartung,et al.  Failure of anti‐GM1 IgG OR IgM to induce conduction block following intraneural transfer , 1995, Muscle & nerve.

[115]  T. Miyatake,et al.  Molecular mimicry between GQ1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome , 1994, Annals of neurology.

[116]  H. Hartung,et al.  T lymphocyte recognition sites on peripheral nerve myelin P0 protein , 1994, Journal of Neuroimmunology.

[117]  A. Vincent,et al.  Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release , 1994, The Lancet.

[118]  R. Hughes,et al.  Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy , 1993, Journal of Neuroimmunology.

[119]  M. Blaser,et al.  Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China , 1993, Annals of neurology.

[120]  R. Hughes,et al.  T cell responses to myelin proteins in Guillain-Barré syndrome , 1992, Journal of the Neurological Sciences.

[121]  A. Colchester,et al.  Subacute idiopathic demyelinating polyradiculoneuropathy. , 1992, Archives of neurology.

[122]  P. Schmitz,et al.  A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. , 1992, The New England journal of medicine.

[123]  H. Jones,et al.  Guillain–Barré syndrome in children: Clinical course, electrodiagnosis, and prognosis , 1992, Muscle & nerve.

[124]  R. Hughes,et al.  Motor nerve biopsy in severe Guillain‐Barré syndrome , 1992, Annals of neurology.

[125]  G. Mckhann,et al.  Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China , 1991, The Lancet.

[126]  W. Brown,et al.  Patterns and severity of conduction abnormalities in Guillain-Barré syndrome. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[127]  M. Blaser,et al.  Campylobacter serology in patients with Chinese paralytic syndrome , 1991, The Lancet.

[128]  B. Shahani,et al.  Electrodiagnostic abnormalities in 113 consecutive patients with Guillain-Barré syndrome. , 1990, Archives of neurology.

[129]  M. Aminoff,et al.  Electrodiagnostic features of the Guillain‐Barré syndrome , 1990, Neurology.

[130]  D. Cornblath.  Electrophysiology in Gullian‐Barré syndeome , 1990 .

[131]  D. Cornblath,et al.  Assessment of current diagnostic criteria for Guillain‐Barré syndrome , 1990, Annals of neurology.

[132]  J. Albers,et al.  Acquired inflammatory demyelinating polyneuropathies: Clinical and electrodiagnostic features , 1989, Muscle & nerve.

[133]  G. Mckhann,et al.  Plasmapheresis and guillain‐barré syndrome: Analysis of prognostic factors and the effect of plasmapheresis , 1988, Annals of neurology.

[134]  D. Griffin,et al.  Immunologic studies of rabies vaccination‐induced Guillain‐Barré syndrome , 1988, Neurology.

[135]  R. Fross,et al.  Neuropathy in the Miller Fisher syndrome , 1987, Neurology.

[136]  R. Hughes,et al.  P0 myelin protein produces experimental allergic neuritis in Lewis rats , 1987, Journal of the Neurological Sciences.

[137]  J. Anderson,et al.  Neuropathological findings in Miller Fisher syndrome. , 1984, Journal of neurology, neurosurgery, and psychiatry.

[138]  W. Brown,et al.  Conduction block and denervation in Guillain-Barré polyneuropathy. , 1984, Brain : a journal of neurology.

[139]  L. Schonberger,et al.  Guillain‐Barré syndrome in the United States, 1978–1981 , 1983, Neurology.

[140]  C. Gorodezky,et al.  HLA-DR antigens in Mexican patients with Guillain-Barré syndrome , 1983, Journal of Neuroimmunology.

[141]  E. Bickerstaff,et al.  Brainstem encephalitis and the syndrome of Miller Fisher: a clinical study. , 1982, Brain : a journal of neurology.

[142]  L. Schonberger,et al.  Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination. , 1982, JAMA.

[143]  J. Mcleod,et al.  Electrophysiological studies in the Guillain‐Barré syndrome , 1981, Annals of neurology.

[144]  J. Prineas.  Pathology of the Guillain‐Barré syndrome , 1981, Annals of neurology.

[145]  R. Hughes,et al.  Identification of the neuritogen for experimental allergic neuritis , 1979, Nature.

[146]  R. Guiloff.  Peripheral nerve conduction in Miller Fisher syndrome. , 1977, Journal of neurology, neurosurgery, and psychiatry.

[147]  R. Adams,et al.  The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. , 1969, Medicine.

[148]  M. Fisher.  An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). , 1956, The New England journal of medicine.